RecruitingNCT05909501

Assessment of Geriatric Evaluations Impact on New AML Guidance

AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

100 participants

Start Date

Oct 25, 2023

Study Type

OBSERVATIONAL

Conditions

AML, Adult

Summary

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Eligibility

Min Age: 50 Years

Inclusion Criteria4

AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
New diagnosis being considered for new line of treatment
Age ≥ 50 years.
Performance status 0,1, and 2

Exclusion Criteria2

Inability to understand or unable to sign a written informed consent
Unable to fill out questionnaires on their own and/or do not have someone to help complete them